A 3D-printed microfluidic gradient generator with integrated photonic silicon sensors for rapid antimicrobial susceptibility testing. Issue 24 (22nd November 2022)

• Record Type: Journal Article
• Authors: Heuer, Christopher; Preuss, John-Alexander; Buttkewitz, Marc; Scheper, Thomas; Segal, Ester; Bahnemann, Janina
• Is Part Of: Lab on a chip. Volume 22:Issue 24(2022)
• Page Start: 4950
• Page End: 4961
• Publication Date: 2022-11-22
• Subjects: Miniature electronic equipment -- Periodicals; Combinatorial chemistry -- Periodicals; Biotechnology -- Periodicals; 543.0813
• DOI: 10.1039/d2lc00640e
• Languages: English
• ISSNs: 1473-0197

Abstract

Abstract : A 3D-printed gradient generator for automated and expeditious on-chip antimicrobial susceptibility testing in a label-free manner is presented, paving the way towards clinical point-of-care applications. Abstract : With antimicrobial resistance becoming a major threat to healthcare settings around the world, there is a paramount need for rapid point-of-care antimicrobial susceptibility testing (AST) diagnostics. Unfortunately, most currently available clinical AST tools are lengthy, laborious, or are simply inappropriate for point-of-care testing. Herein, we design a 3D-printed microfluidic gradient generator that automatically produces two-fold dilution series of clinically relevant antimicrobials. We first establish the compatibility of these generators for classical AST ( i.e., broth microdilution) and then extend their application to include a complete on-chip label-free and phenotypic AST. This is accomplished by the integration of photonic silicon chips, which provide a preferential surface for microbial colonization and allow optical tracking of bacterial behavior and growth at a solid–liquid interface in real-time by phase shift reflectometric interference spectroscopic measurements (PRISM). Using Escherichia coli and ciprofloxacin as a model pathogen-drug combination, we successfully determine the minimum inhibitory concentration within less than 90 minutes. This gradient generator-based PRISM assay provides an integrated AST device that is viable for convenient point-of-care testing and offers a promising and most importantly, rapid alternative to current clinical practices, which extend to 8–24 h.